Altimmune Inc
ALT3.639USD
+0.029+0.81%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
283.21MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Altimmune Inc Unternehmen
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Unternehmensinformationen
BörsenkürzelALT
Name des UnternehmensAltimmune Inc
IPO-datumOct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
Anzahl der mitarbeiter59
WertpapierartOrdinary Share
GeschäftsjahresendeOct 06
Addresse910 Clopper Road
StadtGAITHERSBURG
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl20878-1361
Telefon12406541450
Websitehttps://altimmune.com/
BörsenkürzelALT
IPO-datumOct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
+5.96%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
34.90K
+138.08%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
2.77K
--
Dr. Catherine Angell (Cathy) Sohn, Pharm.D.
Dr. Catherine Angell (Cathy) Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
Mr. Philip L. Hodges
Mr. Philip L. Hodges
Independent Director
Independent Director
--
--
Mr. Jerome Benedict (Jerry) Durso
Mr. Jerome Benedict (Jerry) Durso
Director
Director
--
--
Dr. M. Scot Roberts, Ph.D.
Dr. M. Scot Roberts, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
+5.96%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
34.90K
+138.08%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
2.77K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Jul 29
Aktualisiert: Tue, Jul 29
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
6.82%
The Vanguard Group, Inc.
5.42%
State Street Global Advisors (US)
4.18%
Tang Capital Management, LLC
3.39%
Geode Capital Management, L.L.C.
2.10%
Other
78.09%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
6.82%
The Vanguard Group, Inc.
5.42%
State Street Global Advisors (US)
4.18%
Tang Capital Management, LLC
3.39%
Geode Capital Management, L.L.C.
2.10%
Other
78.09%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
21.43%
Investment Advisor/Hedge Fund
14.99%
Hedge Fund
8.48%
Research Firm
2.10%
Individual Investor
0.76%
Bank and Trust
0.36%
Pension Fund
0.23%
Insurance Company
0.04%
Other
51.61%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
412
39.48M
48.67%
-13.27M
2025Q1
433
39.51M
48.72%
-15.43M
2024Q4
439
41.91M
54.50%
-15.25M
2024Q3
440
40.83M
57.43%
-21.59M
2024Q2
436
43.67M
61.47%
-20.29M
2024Q1
418
45.76M
64.68%
-11.45M
2023Q4
387
34.44M
49.06%
-14.90M
2023Q3
368
31.34M
59.36%
-25.59M
2023Q2
362
36.16M
68.78%
-25.80M
2023Q1
371
44.34M
90.01%
-16.05M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
5.53M
6.82%
-133.00K
-2.35%
Mar 31, 2025
The Vanguard Group, Inc.
4.39M
5.42%
-24.15K
-0.55%
Mar 31, 2025
State Street Global Advisors (US)
3.39M
4.18%
-78.45K
-2.26%
Mar 31, 2025
Tang Capital Management, LLC
2.75M
3.39%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.71M
2.1%
+47.38K
+2.86%
Mar 31, 2025
Two Sigma Investments, LP
1.41M
1.74%
+741.11K
+110.45%
Mar 31, 2025
Columbia Threadneedle Investments (UK)
1.32M
1.63%
-3.78M
-74.03%
Mar 31, 2025
Marshall Wace LLP
1.17M
1.44%
+1.10M
+1683.26%
Mar 31, 2025
Knoll Capital Management, LLC
1.12M
1.38%
--
--
Mar 31, 2025
Millennium Management LLC
1.11M
1.37%
+765.66K
+221.52%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Roundhill GLP-1 & Weight Loss ETF
2.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.32%
Federated Hermes MDT Small Cap Core ETF
0.27%
Amplify Weight Loss Drug & Treatment ETF
0.22%
SPDR S&P Biotech ETF
0.1%
Fidelity Enhanced Small Cap ETF
0.07%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
Invesco Nasdaq Biotechnology ETF
0.03%
Mehr Anzeigen
Roundhill GLP-1 & Weight Loss ETF
Anteil2.06%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.49%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.32%
Federated Hermes MDT Small Cap Core ETF
Anteil0.27%
Amplify Weight Loss Drug & Treatment ETF
Anteil0.22%
SPDR S&P Biotech ETF
Anteil0.1%
Fidelity Enhanced Small Cap ETF
Anteil0.07%
iShares Micro-Cap ETF
Anteil0.07%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.06%
Invesco Nasdaq Biotechnology ETF
Anteil0.03%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
